SEC Form 4 · accession 0001144204-17-048230
Bionik Laboratories Corp. · BNKL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Eric Michel Dusseux
Officer — Chief Executive Officer · Director
Period of report
Sep 1, 2017
Accepted (ET)
Sep 15, 2017 · 2:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001508381
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1,F2 | $0.161 | Sep 1, 2017 | A | 6,107,677 | A | — | Sep 1, 2027 | Common Stock, par value $0.001 | 6,107,677 | 6,107,677 | D |
Explanation of responses
- F1One-sixth of the option will be vested and exercisable as of the September 1, 2017 date of grant, and the unvested portion of the option will become vested and exercisable as follows: (a) 50% in 5 equal annual installments on each of the five anniversaries of the date of the issuance of the option; and (b) 50% in 5 equal separate tranches annually based on Dr. Dusseux's achievement of annual performance goals to be established by the Board in consultation with Dr. Dusseux.
- F2The extent to which each separate tranche becomes vested shall be determined by reference to Dr. Dusseux's annual performance as measured by reference to the performance targets set for that performance period. In the event a specific tranche is not fully vested, that tranche shall not be forfeited, but shall remain outstanding, and may become vested as a result of Dr. Dusseux's future performance at an above target level or as a result of accelerated vesting on the occurrence of any other event that triggers accelerated vesting.